CN103002913B - 靶向产生i型干扰素的细胞的组合物和方法 - Google Patents

靶向产生i型干扰素的细胞的组合物和方法 Download PDF

Info

Publication number
CN103002913B
CN103002913B CN201180016427.5A CN201180016427A CN103002913B CN 103002913 B CN103002913 B CN 103002913B CN 201180016427 A CN201180016427 A CN 201180016427A CN 103002913 B CN103002913 B CN 103002913B
Authority
CN
China
Prior art keywords
antibody
immunoglobulin
days
cells
mammal
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201180016427.5A
Other languages
English (en)
Chinese (zh)
Other versions
CN103002913A (zh
Inventor
基诺·路易吉·瓦伊洛
安德鲁·纳什
尤金·马拉斯阔夫斯基
尼克·威尔逊
萨曼塔·布斯菲尔德
帕努斯·康
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
CSL Ltd
Original Assignee
CSL Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=44482392&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CN103002913(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from US12/707,297 external-priority patent/US20100209341A1/en
Application filed by CSL Ltd filed Critical CSL Ltd
Publication of CN103002913A publication Critical patent/CN103002913A/zh
Application granted granted Critical
Publication of CN103002913B publication Critical patent/CN103002913B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39566—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against immunoglobulins, e.g. anti-idiotypic antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C07K2317/41—Glycosylation, sialylation, or fucosylation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Transplantation (AREA)
  • Rheumatology (AREA)
  • Hematology (AREA)
  • Pain & Pain Management (AREA)
  • Oncology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CN201180016427.5A 2010-02-17 2011-02-17 靶向产生i型干扰素的细胞的组合物和方法 Active CN103002913B (zh)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US12/707,297 2010-02-17
US12/707,297 US20100209341A1 (en) 2009-02-18 2010-02-17 Treatment of chronic inflammatory conditions
US37448910P 2010-08-17 2010-08-17
US37449710P 2010-08-17 2010-08-17
US61/374,497 2010-08-17
US61/374,489 2010-08-17
PCT/AU2011/000155 WO2011100786A1 (en) 2010-02-17 2011-02-17 Compositions and methods for targeting type 1 interferon producing cells

Publications (2)

Publication Number Publication Date
CN103002913A CN103002913A (zh) 2013-03-27
CN103002913B true CN103002913B (zh) 2015-12-16

Family

ID=44482392

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201180016427.5A Active CN103002913B (zh) 2010-02-17 2011-02-17 靶向产生i型干扰素的细胞的组合物和方法

Country Status (10)

Country Link
EP (1) EP2536430B1 (enExample)
JP (1) JP6018507B2 (enExample)
KR (1) KR101842907B1 (enExample)
CN (1) CN103002913B (enExample)
AU (1) AU2011217728B2 (enExample)
CA (1) CA2789810C (enExample)
ES (1) ES2618562T3 (enExample)
IL (1) IL221504B (enExample)
NZ (2) NZ610826A (enExample)
WO (1) WO2011100786A1 (enExample)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100209341A1 (en) 2009-02-18 2010-08-19 Csl Limited Treatment of chronic inflammatory conditions
EP2839842A1 (en) 2013-08-23 2015-02-25 MacroGenics, Inc. Bi-specific monovalent diabodies that are capable of binding CD123 and CD3 and uses thereof
AR103488A1 (es) 2015-01-23 2017-05-10 Sanofi Sa Anticuerpos anti-cd3, anticuerpos anti-cd123 y anticuerpos biespecíficos que se unen específicamente a cd3 y/o cd123
TW201709932A (zh) 2015-06-12 2017-03-16 西雅圖遺傳學公司 Ｃｄ１２３抗體及其共軛物
EP3448995A1 (en) * 2016-04-25 2019-03-06 Universität Basel Allele editing and applications thereof
CN113286812B (zh) 2018-09-27 2025-05-30 西里欧发展公司 掩蔽型细胞因子多肽
EP4251187A4 (en) 2020-11-25 2025-09-10 Xilio Dev Inc TUMOR-SPECIFIC CLASSIBLE LINKERS
KR20250152662A (ko) 2020-12-31 2025-10-23 사노피 NKp46 및 CD123에 결합하는 다기능성 자연살해(NK) 세포 관여자
WO2023227790A1 (en) 2022-05-27 2023-11-30 Sanofi Natural killer (nk) cell engagers binding to nkp46 and bcma variants with fc-engineering
WO2025151752A1 (en) 2024-01-10 2025-07-17 Xilio Development, Inc. Masked il-2 cytokines and methods of use thereof

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008024188A2 (en) * 2006-08-18 2008-02-28 Abbott Laboratories Dual variable domain immunoglobulin and uses thereof
WO2008127735A1 (en) * 2007-04-13 2008-10-23 Stemline Therapeutics, Inc. Il3ralpha antibody conjugates and uses thereof
WO2009070844A1 (en) * 2007-12-06 2009-06-11 Csl Limited Method of inhibition of leukemic stem cells

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002090510A2 (en) * 2001-05-08 2002-11-14 Emory University Regulating immine responses using dendritic cells
EP3207941B3 (en) * 2006-09-07 2020-08-19 Scott & White Memorial Hospital Methods and compositions based on diphtheria toxin-interleukin-3 conjugates
JP2008162954A (ja) * 2006-12-28 2008-07-17 Kirin Pharma Co Ltd 形質細胞様樹状細胞特異的膜分子に対する抗体を含む治療剤
US20100209341A1 (en) * 2009-02-18 2010-08-19 Csl Limited Treatment of chronic inflammatory conditions

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008024188A2 (en) * 2006-08-18 2008-02-28 Abbott Laboratories Dual variable domain immunoglobulin and uses thereof
WO2008127735A1 (en) * 2007-04-13 2008-10-23 Stemline Therapeutics, Inc. Il3ralpha antibody conjugates and uses thereof
WO2009070844A1 (en) * 2007-12-06 2009-06-11 Csl Limited Method of inhibition of leukemic stem cells

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
Monoclonal antibody 7G3 recognizes the N-terminal domain of the human interleukin-3(IL-3) receptor alpha-chain and functions as a specific IL-3;Sun Q et al.;《Blood》;19960101;第87卷(第1期);83-92 *
Monoclonal antibody-mediated targeting of CD123,IL-3 receptor alpha chain,eliminates human acute myeloid leukemic stem cells;Jin L et al.;《Cell stem cell》;20090702;第5卷(第1期);31-42 *

Also Published As

Publication number Publication date
NZ601760A (en) 2013-10-25
AU2011217728A1 (en) 2012-09-06
EP2536430A4 (en) 2013-09-04
ES2618562T3 (es) 2017-06-21
AU2011217728B2 (en) 2013-03-14
KR20130004576A (ko) 2013-01-11
NZ610826A (en) 2015-01-30
IL221504B (en) 2019-06-30
JP2013519690A (ja) 2013-05-30
CN103002913A (zh) 2013-03-27
KR101842907B1 (ko) 2018-03-28
WO2011100786A1 (en) 2011-08-25
EP2536430B1 (en) 2016-12-14
CA2789810C (en) 2020-12-01
EP2536430A1 (en) 2012-12-26
CA2789810A1 (en) 2011-08-25
JP6018507B2 (ja) 2016-11-02

Similar Documents

Publication Publication Date Title
US9758585B2 (en) Compositions and methods for targeting type 1 interferon producing cells
US10047161B2 (en) Humanized anti-interleukin 3 receptor alpha chain antibodies
EP2536430B1 (en) Compositions and methods for targeting type 1 interferon producing cells
US20180244786A1 (en) Anti il-3r alpha agents and uses thereof
US20180208661A1 (en) Agents that neutralize il-3 signalling and uses thereof
JP2013519690A5 (enExample)
AU2013200910B2 (en) Composition and methods for targeting type 1 interferon producing cells
AU2012202125B2 (en) Humanized Anti-Interleukin 3 Receptor Alpha Chain Antibodies
HK1179884B (en) Compositions and methods for targeting type 1 interferon producing cells
HK1179884A (en) Compositions and methods for targeting type 1 interferon producing cells
HK1181785B (en) Humanized anti-interleukin 3 receptor alpha chain antibodies
HK1181785A (en) Humanized anti-interleukin 3 receptor alpha chain antibodies
AU2011253598B1 (en) Humanized anti-interleukin 3 receptor alpha chain antibodies

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C53 Correction of patent of invention or patent application
CB03 Change of inventor or designer information

Inventor after: Vairo Gino Luigi

Inventor after: Nash Andrew

Inventor after: Maraskovsky Eugene

Inventor after: Wilson Nick

Inventor after: Busfield Samantha

Inventor after: Kang Kang

Inventor before: Vairo Gino Luigi

Inventor before: Nash Andrew

Inventor before: Maraskovsky Eugene

Inventor before: Wilson Nick

Inventor before: Busfield Samantha

COR Change of bibliographic data

Free format text: CORRECT: INVENTOR; FROM: VAIRO GINO LUIGI NASH ANDREW MARASKOVSKY EUGENE WILSON NICK BUSFIELD SAMANTHA TO: VAIRO GINO LUIGI NASH ANDREW MARASKOVSKY EUGENE WILSON NICK BUSFIELD SAMANTHA PANOUSIS CON

C14 Grant of patent or utility model
GR01 Patent grant